Vaxart soars on early-stage data of its new norovirus vaccine
Shares of drug developer Vaxart VXRT.O rise 81.2% to 71 cents premarket
Co says its new experimental norovirus vaccine produced significantly stronger immune responses than the original version in an early-stage trial
VXRT says that the second generation vaccine increased protective antibodies by 141% for one strain of norovirus and 94% for another
Co claimed that even at lower doses, the new vaccine performed better than VXRT's original version and all vaccines tested were well-tolerated with no serious side effects
As of last close, VXRT stock down 40.7% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Meme Stocks Reappear. Avis Shares Reach New Highs Amid Short Squeeze. Can Retail Investors Still Buy?

Tesla Q1 2026 Earnings Preview: 50,000-Unit Inventory Overhang, Energy Storage Halved, 5 Core Metrics Long-Term Investors Should Really Watch

Bitmine 2030 Stock Price Prediction: Why Did BMNR Stock Price Fall? How High Will It Rise in the Future?

Strike Threat Could Cost 30 Trillion Won, Can Samsung’s Stock Rally Last?

NVDA Stock vs Micron Technology Stock: Why AI Memory Demand Could Outpace Nvidia’s Next Growth Phase

Tradingkey






